Bayer Schering looks to broaden Nexavar's use across Asia
This article was originally published in Scrip
Executive Summary
In line with its global strategy for the product, Bayer Schering Pharma (BSP) is developing the oral multikinase inhibitor Nexavar (sorafenib) for a range of additional indications across the Asia-Pacific region.